Sanofi (EPA:SAN)
103.40
+1.54 (1.51%)
Mar 28, 2025, 5:35 PM CET
Sanofi Revenue
In the year 2024, Sanofi had annual revenue of 44.29B EUR with 7.73% growth. Sanofi had revenue of 11.42B in the quarter ending December 31, 2024.
Revenue
44.29B
Revenue Growth
+7.73%
P/S Ratio
2.92
Revenue / Employee
534.35K
Employees
82,878
Market Cap
126.57B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 26.51B |
Sartorius Stedim Biotech | 2.78B |
bioMérieux | 3.98B |
Eurofins Scientific SE | 6.95B |
Ipsen | 3.57B |
Virbac | 1.40B |
emeis Société anonyme | 5.43B |
Clariane SE | 5.28B |
Sanofi News
- 4 hours ago - Sanofi gets FDA nod for its hemophilia treatment - Seeking Alpha
- 5 hours ago - US FDA approves Sanofi's bleeding disorder therapy - Reuters
- 9 hours ago - AbbVie Vs. Sanofi: Which Is The Better Investment Right Now - Seeking Alpha
- 17 hours ago - Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD - GlobeNewsWire
- 1 day ago - Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate - Fortune
- 2 days ago - Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA - GlobeNewsWire
- 3 days ago - Sanofi gets priority review for its multiple sclerosis treatment by FDA - Seeking Alpha
- 3 days ago - Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis - GlobeNewsWire